Therapeutical impacts of transcranial direct current stimulation on drug-resistant epilepsy in pediatric patients: A double-blind parallel-group randomized clinical trial

Epilepsy Res. 2023 Feb:190:107074. doi: 10.1016/j.eplepsyres.2022.107074. Epub 2023 Jan 5.


Background: Drug-resistant epilepsy is a challenging problem in pediatrics. Transcranial direct current stimulation (TDCS) is a non-invasive neurostimulation technique suggested as a promising method for treating epilepsy. This study aims to evaluate the efficacy of TDCS in focal epilepsy in children with drug-resistant epilepsy.

Method: We conducted a randomized sham-controlled study with 18 subjects between 6 and 16 years of age, divided equally into two groups. TDCS was performed in 20-minute daily stimulation protocol for five days for both groups. The current intensity was one mA for the first three days, increasing to 1.5 mA on day four and 2 mA on the last day of stimulation. EEG was done before and after the intervention.

Results: There was a significant reduction in seizure duration in the case group compared with the sham group.

Conclusion: five consecutive days of performing TDCS significantly reduced seizure duration in children with focal Drug-resistant epilepsy. However,further studies in this field are necessary to test the effectiveness and set up a coherent and comprehensive protocol.

Keywords: Drug Resistant Epilepsy; Pediatrics; Transcranial direct current stimulation.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Child
  • Double-Blind Method
  • Drug Resistant Epilepsy* / therapy
  • Epilepsies, Partial* / therapy
  • Humans
  • Seizures / therapy
  • Transcranial Direct Current Stimulation* / methods